Areas of consensus at APCCC last year … see Table 1

Posted on February 7, 2020 by Sitemaster

So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , , , | 2 Comments »

ADT + darolutamide extends overall survival in men with nmCRPC

Posted on February 3, 2020 by Sitemaster

According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 2 Comments »

FDA approves darolutamide for treatment of nmCRPC

Posted on July 31, 2019 by Sitemaster

Bayer’s US pharmaceutical division has announced that the US Food and Drug Administration (FDA) has approved darolutamide — their formerly investigational androgen receptor inhibitor — for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 3 Comments »

Darolutamide (ODM-201) in the treatment of nmCRPC

Posted on March 28, 2019 by Sitemaster

Earlier this year we had reported on the initial presentation of data demonstrating the efficacy and safety of darolutamide (formerly known as ODM-201), a third “super-antiandrogen” — similar to enzalutamide (Xtandi) and apalutamide (Erleada), in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Uncategorized | Tagged: , , , , , | Leave a comment »

Darolutamide (ODM-201) in the treatment of nmCRPC

Posted on February 15, 2019 by Sitemaster

Also on Thursday in San Francisco, Dr. Karim Fizazi presented the initial results from the ARAMIS trial of darolutamide (formerly known as ODM-201) in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Filed under: Uncategorized | Tagged: , , , , , | 6 Comments »

Apalutamide (Erleada) approved in EU for treatment of nmCRPC

Posted on January 17, 2019 by Sitemaster

Yesterday, Janssen Pharmaceuticals announced the approval of apalutamide (Erleada) by the European Commission (EC) for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk for development of metastatic disease. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | 2 Comments »

Evolution in the management of nmCRPC

Posted on August 21, 2018 by Sitemaster

With the relatively recent approvals of apalutamide (Erleada) and enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), we are seeing intense discussion within the urologic oncology and medical oncology communities about the appropriate treatment of patients with this category of prostate cancer. … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 3 Comments »

Next Page »